



November 4, 2015

## **Revance Therapeutics to Release Third Quarter 2015 Financial Results Monday, November 9, 2015**

### **Conference Call Scheduled for Monday, November 9, 2015 at 4:30pm ET**

NEWARK, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today that the Company will release third quarter 2015 financial results on Monday, November 9, 2015 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business update.

Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 48748347; or from the webcast link in the investor relations section of the Company's website at: [www.revance.com](http://www.revance.com).

A replay of the call will be available beginning November 9, 2015 at 4:30pm PT/7:30pm ET through midnight on November 10, 2015. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 48748347. The webcast will be available in the investor relations section on the Company's website for 30 days following the completion of the call.

### **About Revance Therapeutics, Inc.**

Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel drug product candidates, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a targeted and potentially long-lasting delivery. Revance is pursuing clinical development for drug product candidates RT001 topical and RT002 injectable in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. More information on Revance Therapeutics can be found at [www.revance.com](http://www.revance.com).

*"Revance Therapeutics", TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc.*

CONTACT: Investor Contact

Revance Therapeutics

Jeanie Herbert

(714) 325-3584

[jherbert@revance.com](mailto:jherbert@revance.com)

Westwicke Partners

Leigh Salvo

(415) 513-1281

[leigh.salvo@westwicke.com](mailto:leigh.salvo@westwicke.com)

Trade Media Contact

Nadine Tosk

(847) 920-9858

[nadinepr@gmail.com](mailto:nadinepr@gmail.com)

Source: Revance Therapeutics, Inc.

News Provided by Acquire Media